BACKGROUND: @entity6800 ( @entity6800 ) is expressed in upper airways, however, little is known regarding whether @entity6800 ( @entity6800 ) signals exert a regulatory effect on the pathogenesis of chronic rhinosinusitis with @entity480 (CRSwNP), especially on @entity32 . We sought to investigate the effect of Poly(IC), the ligand for @entity6800 , on cytokine production by dispersed nasal polyp cells (DNPCs). METHODS: DNPCs were pretreated with or without Poly(IC), and were then cultured in the presence or absence of staphylococcal enterotoxin B (SEB), following which the levels of @entity225 , @entity688 , @entity4047 , @entity4155 and @entity379 in the supernatant were measured. To determine the involvement of @entity688 and cyclooxygenase in Poly(IC)-mediated signaling, DNPCs were treated with anti- @entity688 monoclonal antibody and @entity3522 , the cyclooxygenase inhibitor, respectively. @entity14018 -induced @entity1421 ( @entity1421 ) production was also determined. RESULTS: Exposure to @entity14018 induced a significant production of @entity688 , but not of @entity225 , @entity4047 , @entity4155 or @entity379 by DNPCs. Pretreatment with @entity14018 dose-dependently inhibited SEB-induced @entity225 , @entity4047 and @entity4155 , but not @entity379 production. Neutralization of @entity688 significantly abrogated the inhibitory effect of @entity14018 . Treatment with @entity3522 also abrogated the inhibitory effect of @entity14018 on SEB-induced @entity225 and @entity4047 production. However, unlike exposure of @entity3522 -treated DNPCs to lipopolysaccharide, the ligand for @entity2939 , exposure of these cells to @entity14018 did not enhance @entity225 or @entity4047 production. Poly(IC) did not significantly increase @entity1421 production by DNPCs. CONCLUSIONS: These results suggest that @entity6800 signaling regulates @entity1712 -associated cytokine production in CRSwNP, at least in part, via @entity688 production.

Regulatory effect of @entity6800 signaling on staphylococcal enterotoxin-induced XXXX , @entity4047 , @entity4155 and @entity379 production in chronic rhinosinusitis with @entity480 .

@entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity6800 :: ('7098', 'Gene') :: ['Toll-like receptor 3', 'TLR3'] @entity32 :: ('MESH:D007249', 'Disease') :: ['eosinophilic inflammation'] @entity225 :: ('3567', 'Gene') :: ['IL-5'] @entity14018 :: ('MESH:D011070', 'Chemical') :: ['Poly(IC)'] @entity4047 :: ('3596', 'Gene') :: ['IL-13'] @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2'] @entity688 :: ('3586', 'Gene') :: ['IL-10'] @entity4155 :: ('3605', 'Gene') :: ['IL-17A'] @entity379 :: ('3458', 'Gene') :: ['IFN-y', 'interferon (IFN)-y'] @entity2939 :: ('7099', 'Gene') :: ['TLR4'] @entity480 :: ('MESH:D009298', 'Disease') :: ['nasal polyps']
@entity225 :: (3567,Gene) :: ['IL-5']
